Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all

被引:44
|
作者
Grebely, Jason [1 ]
Hajarizadeh, Behzad [1 ]
Lazarus, Jeffrey V. [2 ]
Bruneau, Julie [3 ,4 ]
Treloar, Carla [5 ]
机构
[1] UNSW Sydney, Kirby Inst, Sydney, NSW, Australia
[2] Univ Barcelona, Barcelona Inst Global Hlth ISGlobal, Hosp Clin, Barcelona, Spain
[3] Ctr Hosp Univ Montreal, CHUM Res Ctr, Montreal, PQ, Canada
[4] Univ Montreal, Dept Family & Emergency Med, Fac Med, Montreal, PQ, Canada
[5] UNSW Sydney, Ctr Social Res Hlth, Sydney, NSW, Australia
基金
英国医学研究理事会;
关键词
HCV; Drug users; Injecting; Treatment; Care; Access; PWID; SUSTAINED VIROLOGICAL RESPONSE; PRESCRIPTION OPIOID INJECTION; HCV INFECTION; RISK-FACTORS; GLOBAL PREVALENCE; UNITED-STATES; PEER SUPPORT; LATE RELAPSE; HEALTH-CARE; NEW-YORK;
D O I
10.1016/j.drugpo.2019.07.016
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
There have been major strides towards the World Health Organization goal to eliminate hepatitis C virus (HCV) infection as a global public health threat. The availability of simple, well-tolerated direct-acting antiviral therapies for HCV infection that can achieve a cure in > 95% of people has provided an important tool to help achieve the global elimination targets. Encouragingly, therapy is highly effective among people receiving opioid agonist therapy and people who have recently injected drugs. Moving forward, major challenges include ensuring that new infections are prevented from occurring and that people who are living with HCV are tested, linked to care, treated, receive appropriate follow-up, and have equitable access to care. This editorial highlights key themes and articles in a special issue focusing on the elimination of HCV among people who inject drugs. An overarching consideration flowing from this work is how to ensure equitable access to HCV treatment and care for all. This special issue maps the field in relation to: HCV prevention; the cascade of HCV care; strategies to enhance testing, linkage to care, and treatment uptake; and HCV treatment and reinfection. In addition, papers draw attention to the 'risk environments' and socio-ecological determinants of HCV acquisition, barriers to HCV care, the importance of messaging around the side-effects of new direct-acting antiviral therapies, the positive transformative potential of treatment and cure, and the key role of community-based drug user organizations in the HCV response. While this special issue highlights some successful efforts towards HCV elimination among people who inject drugs, it also highlights the relative lack of attention to settings in which resources enabling elimination are scarce, and where elimination hopes and potentials are less clear, such as in many low and middle income countries. Strengthening capacity in areas of the world where resources are more limited will be a critical step towards ensuring equity for all so that global HCV elimination among PWID can be achieved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [1] Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs
    Grebely, Jason
    Bruggmann, Philip
    Treloar, Carla
    Byrne, Jude
    Rhodes, Tim
    Dore, Gregory J.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2015, 26 (10) : 893 - 898
  • [2] Prevention, treatment and care of hepatitis C virus infection among people who inject drugs
    Bruggmann, Philip
    Grebely, Jason
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2015, 26 : S22 - S26
  • [4] Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements
    Grebely, Jason
    Matthews, Gail V.
    Lloyd, Andrew R.
    Dore, Gregory J.
    CLINICAL INFECTIOUS DISEASES, 2013, 57 (07) : 1014 - 1020
  • [5] Models of care for the management and treatment of hepatitis C virus infection among people who inject drugs
    Conti, F.
    Borghi, A.
    Lanzi, A.
    Bevilacqua, V.
    Vignoli, T.
    Olivoni, D.
    Greco, G.
    Sanza, M.
    Polidori, E.
    Bassi, P.
    Foschi, F. G.
    DIGESTIVE AND LIVER DISEASE, 2019, 51 : E60 - E61
  • [6] MODELS OF CARE FOR THE MANAGEMENT AND TREATMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS
    Conti, Fabio
    Borghi, Alberto
    Lanzi, Arianna
    Bevilacqua, Vittoria
    Vignoli, Teo
    Olivoni, Deanna
    Greco, Giovanni
    Sanza, Michele
    Polidori, Edoardo
    Bassi, Paolo
    Grassi, Alberto
    Ballardini, Giorgio
    Piraccini, Pierpaolo
    Sambri, Vittorio
    Foschi, Francesco Giuseppe
    HEPATOLOGY, 2019, 70 : 956A - 956A
  • [7] Hepatitis C virus treatment as prevention in people who inject drugs
    White, Peter J.
    Abubakar, Ibrahim
    LANCET INFECTIOUS DISEASES, 2018, 18 (04): : 379 - 379
  • [8] Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs
    Grebely, Jason
    Bruggmann, Philip
    Treloar, Carla
    Byrne, Jude
    Rhodes, Tim
    Dore, Gregory J.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2015, 26 (11) : 1039 - 1040
  • [9] Hepatitis C Virus Reinfection Following Treatment Among People Who Use Drugs
    Grady, Bart P.
    Schinkel, Janke
    Thomas, Xiomara V.
    Dalgard, Olav
    CLINICAL INFECTIOUS DISEASES, 2013, 57 : S105 - S110
  • [10] Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs
    Foschi, Francesco Giuseppe
    Borghi, Alberto
    Grassi, Alberto
    Lanzi, Arianna
    Speranza, Elvira
    Vignoli, Teo
    Napoli, Lucia
    Olivoni, Deanna
    Sanza, Michele
    Polidori, Edoardo
    Greco, Giovanni
    Bassi, Paolo
    Cristini, Francesco
    Ballardini, Giorgio
    Altini, Mattia
    Conti, Fabio
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)